Debiopharm S.a.

Other

Debio Recherche Pharmaceutique S.a.

Rolland-Yves Mauvernay

Piero Orsolini

Romano Deghenghi

Yoshinori Kidani

Grégoire Vuagniaux

Houssam Ibrahim

Pietro Scalfaro

Jean-Maurice Dumont

Bruno Chauffert

Philippe Genne

Gilles Gutierrez

Teruko Irie

The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.

Oxaliplatin active substance with a very low content of oxalic acid

This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.

Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin

Use of selected cyclosporins for the treatment of hepatitis C infection

Flexible impervious bag for medical use containing a pharmaceutical preparation of liquid oxaliplatinum said flexible bag is constructed from plastic materials, with the proviso that any portion to the bag in direct contact with said pharmaceutical preparation of liquid oxaliplatinum does not contain polyvinylchloride-based plastic material.

Oxalipatinum preparation packaging

Binuclear platinum complexes, method for preparing same and

A pharmaceutical composition for the sustained release of a peptide wherein the composition includes a polylactide polymer, a polymer of lactic acid and glycolic acid, or a mixture of such polymers and a therapeutically active peptide in the form of its pamoate, tannate or stearate salt. The composition when placed in an aqueous physiological environment releases the peptide in a continuous manner for a period of at least about one week.

Sustained and controlled release of water insoluble polypeptides

Pharmaceutically stable preparation of oxaliplatinum

Cinchonine, dihydrocinchonine or hydroquinidine are used as multidrug resistance inhibiting substance in the treatment of cancerous tumors by the use of cytotoxic agents. Particularly, cinchonine, dihydrocinchonine or hydroquinidine are used in the preparation of pharmaceutical compositions used in the treatment of cancerous tumors developing the phenomenon of multidrug resistance. Application to the treatment of human cancers.

Therapeutic agents for the treatment of multiple drug resistance of

There is disclosed a pharaceutical composition for sustained and controlled release of drug over an extended period of time comprising a polylactide, a copolymer of lactic and glycolic acid, a mixture of such polymers and a water-insoluble peptide which, when placed in an aqueous physiologically-type environment releases the peptide in continuous manner for a period of at least one week, and with an initial release for the first twenty-four hours of not more than 30% of the total amount released. There is thus provided the control of the release pattern and in general a decrease of the initial burst effect.

The microencapsulation of medicamentous water-soluble substances is carried out by phase separation. The operations of the hardening step take place at a temperature comprised between about 0.degree. and about 25.degree. C., the non-solvent used during this step being an aliphatic fluorinated or fluorohalogenated hydrocarbon or a mixture of such hydrocarbons. Further, the non-solvent is used in an excess with respect to the volume of solvent and non-solvent resulting from the phase-separation step.

Growing community of inventors

Lausanne, Switzerland

Rolland-Yves Mauvernay